Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

Written By Carra Buttress

- Currently recruiting participants
[UPDATED 08/24/20]

  • City of Hope Comprehensive Cancer Center, Duarte, California

  • Johns Hopkins University, Baltimore, Maryland

  • Weill Cornell Medicine/New York Presbyterian Hospital, New York, New York

  • Barbara Ann Karmanos Cancer Institute, Detroit, Michigan

  • Washington University School of Medicine, St. Louis, Missouri

  • MD Anderson Cancer Center, Houston, Texas 

  • Roswell Park Comprehensive Cancer Center, Buffalo, New York

  • Northwell Health Cancer Institute, New York, New York

- This phase 1 trial is evaluating the safety, tolerability, ability to cause an immune response to the vaccine, and to detect preliminary evidence of anti tumor activity.

-  This is the First in Humans clinical study of Nous-209 genetic vaccine in patients with inoperable or metastatic Mismatch Repair Deficient (dMMR) or Microsatellite Instability High (MSI-H) colorectal, gastric, gastro-esophageal junction and endometrial tumors in hereditary or sporadic (not caused by an inherited gene mutation) forms of the diseases. This vaccine is being used in combination with the immunotherapy drug pembrolizumab (Keytruda).

- Most tumors caused by Lynch Syndrome are dMMR and/or MSI-H

Learn More:
https://clinicaltrials.gov/ct2/show/NCT04041310?term=Nouscom&draw=2&rank=1

Carra Buttress
Previous

Recent research shows there is no evidence of increased risk of breast cancer in women with Lynch Syndrome
Next

Dr. Henry Lynch (January 4, 1928 - June 2, 2019)